Cazzola M

Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome.

Guzzi N, Muthukumar S, Cieśla M, ..., Dimitriou M, Bellodi C

Nat Cell Biol 24 (3) 299-306 [2022-03-00; online 2022-03-15]

Structural Proteomics [Collaborative]

Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms.

Todisco G, Creignou M, Gallì A, ..., Cazzola M, Malcovati L

Leukemia 35 (8) 2371-2381 [2021-08-00; online 2020-12-21]

Clinical Genomics [Service] Clinical Genomics Uppsala [Service]

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E, Nannya Y, Hasserjian RP, ..., Ogawa S, Papaemmanuil E

Nat. Med. 26 (10) 1549-1556 [2020-10-00; online 2020-08-03]

Clinical Genomics [Service] Clinical Genomics Uppsala [Service]

Gene expression and risk of leukemic transformation in myelodysplasia.

Shiozawa Y, Malcovati L, Gallì A, ..., Cazzola M, Ogawa S

Blood 130 (24) 2642-2653 [2017-12-14; online 2017-11-02]

Clinical Genomics [Service] Clinical Genomics Uppsala [Service]